CN104337909B - 一种含九香虫的治疗痛风的中药组合物 - Google Patents
一种含九香虫的治疗痛风的中药组合物 Download PDFInfo
- Publication number
- CN104337909B CN104337909B CN201410628473.6A CN201410628473A CN104337909B CN 104337909 B CN104337909 B CN 104337909B CN 201410628473 A CN201410628473 A CN 201410628473A CN 104337909 B CN104337909 B CN 104337909B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- parts
- gout
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 201000005569 Gout Diseases 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 241000660877 Coridius Species 0.000 title claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 33
- 230000000694 effects Effects 0.000 abstract description 21
- 235000019640 taste Nutrition 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 16
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 16
- 229940116269 uric acid Drugs 0.000 description 16
- 229940079593 drug Drugs 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 201000001431 Hyperuricemia Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 240000000425 Chaenomeles speciosa Species 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 235000005078 Chaenomeles speciosa Nutrition 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000320508 Pentatomidae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 231100000850 chronic interstitial nephritis Toxicity 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种中药组合物，具体涉及一种含九香虫的治疗痛风的中药组合物，属于医药技术领域。本发明的治疗痛风的中药组合物是由以下重量配比的药用原料制成的药剂：佛手4～20份、猫爪草3～15份、川芎3～10份、九香虫3～10份、木瓜3～10份。本发明治疗痛风的中药组合物，5味药用原料按配比组合后，具有协同增效功能，用于治疗痛风疗效显著，且未发现明显的副作用及不良反应。
Description
技术领域
本发明涉及一种中药组合物，具体涉及一种含九香虫的治疗痛风的中药组合物，属于医药技术领域。
背景技术
痛风又称高尿酸血症，发病率高、治愈难、反复发作，属于嘌呤代谢障碍引起的代谢性疾病。痛风多发生于中老年人、肥胖者和脑力劳动者，其临床特点为高尿酸血症及由此引起的痛风性急性关节炎反复发作，痛风石沉积、痛风石性慢性关节炎和关节畸形等，以关节红肿、热痛、反复发作、关节活动不灵活为主要临床表现。常累及肾脏引起慢性间质性肾炎和尿酸肾结石形成。根据血中尿酸增高原因可分为原发性和继发性两大类。原发性痛风的病因是由于先天性嘌呤代谢紊乱所致，属遗传性。继发性痛风的病因，可由肾脏病、白血病、药物、食物等多种原因引起，好发于男性及绝经期女性。
目前用于治疗痛风的西药主要有：秋水仙碱、保泰松或羟基保泰松、消炎痛、布洛芬(ibvprofen，异丁苯丙酸)、炎痛喜康(piroxicanum)、萘普生(naproxen消痛灵)、ACTH及强的松等。但上述药物大多只能稳定病情，不能根治痛风；还会引起严重的副作用造成肝肾功能的损害；即使近期治疗有效也不能控制病情复发，而且可产生耐药性和抵抗性，甚至会出现白细胞减少、心脏功能受损、肝肾功能受损、刺激肠胃系统、再生障碍性贫血、导致糖尿病等合并症。
中医学上，痛风属于“痹证”范畴，《血证论》：“痛风、身体不仁、四肢疼痛、今名痛风、古曰痹证”。越来越多的专家认为，从中医的整体观念出发，用中医药整体辨证施治，不失为治疗痛风疾病的又一条佳径；不但中药本身的毒副作用小，而且可降低西药服用量，克服长期单纯服用西药所带来的巨大毒副作用。
发明内容
本发明的目的在于克服现有技术中所存在西药副作用大、治疗不彻底的上述不足，提供一种含九香虫的治疗痛风的中药组合物，该中药组合物治疗痛风疗效好、见效快，且对患者身体副作用小。
为了实现上述发明目的，本发明提供了以下技术方案：
一种含九香虫的治疗痛风的中药组合物，它是由以下重量配比的药用原料制备而成：佛手4～20份、猫爪草3～15份、川芎3～10份、九香虫3～10份、木瓜3～10份。所述各种药用原料均为符合国家或地方标准规定的中药材。
优选的，上述药用原料配比中，佛手所占重量比例为8～15份。更优选的，佛手所占重量比例为12份。
优选的，上述药用原料配比中，猫爪草所占重量比例为6～10份。更优选的，猫爪草所占重量比例为8份。
优选的，上述药用原料配比中，川芎所占重量比例为4～7份。更优选的，川芎所占重量比例为6份。
优选的，上述药用原料配比中，九香虫所占重量比例为4～7份。更优选的，九香虫所占重量比例为6份。
优选的，上述药用原料配比中，木瓜所占重量比例为4～7份。更优选的，木瓜所占重量比例为6份。
本发明的治疗痛风的中药组合物，可以按照中药学上常规的提取方法提取药用原料的活性组分，再加上药学上可接受的载体或/和辅料，如淀粉、糊精、微晶纤维、可压性淀粉、硬脂酸镁、微粉硅胶、蔗糖、羧甲基淀粉钠、羟丙基甲基纤维素、植物油、卵磷脂、聚乙二醇、丙二醇、尼泊金乙酯等，制成药剂学上适宜的剂型，如颗粒剂、片剂、硬胶囊、口服液、软胶囊、滴丸、水泛丸等。
本发明中药组合物的提取方法可以采用但不限于以下方法：
(1)按配方比例取各药用原料，向药用原料中加入药用原料体积8～10倍的60～80％乙醇或水；回流提取2～3次；提取时间分别为1～2h；收集合并提取液，并将提取液浓缩成浸膏，干燥，得到本发明的药用原料的提取物。
(2)向上述提取物中加入药用辅料混合制成药剂学上可接受的各种药物剂型。
根据制备各种剂型药物的需要，本发明药物在制备过程中还可加入适当的药用辅料如填充剂、崩解剂、粘合剂、润滑剂、防腐剂等。
与现有技术相比，本发明的有益效果：
本发明治疗痛风的中药组合物，是发明人基于祖国医学对痛风的发病机理的认识，根据自己多年临床经验，先从众多中药中确定一系列治疗痛风有效的中药，再经临床反复验证，而筛选出来的。其中，佛手，别名佛手柑、手柑；为芸香科柑橘属植物佛手的干燥果实；辛、苦、酸，温；归肝、脾、肺经；具有舒肝理气、和胃止痛的功效；用于肝胃气滞、胸胁胀痛、胃脘痞满、食少呕吐等症。猫爪草，为毛茛科植物小毛茛的干燥块根；甘、辛，温；归肝、肺经；具有散结、消肿的功能；用于瘰疬未溃、淋巴结结核等症。川芎，别名芎藭、小叶川芎；为伞形科植物川芎的干燥根茎；辛，温；归肝、胆、心包经；具有活血行气、祛风止痛的功效；用于月经不调，经闭痛经，症瘕腹痛，胸胁刺痛，跌扑肿痛，头痛，风湿痹痛等症。九香虫，为蝽科昆虫九香虫的干燥体；咸，温；归肝、脾、肾经；具有理气止痛、温中助阳的功效；用于胃寒胀痛、肝胃气痛、肾虚阳痿、腰膝酸痛的功效；木瓜，别名贴梗海棠、铁脚梨、皱皮木瓜、宣木瓜，为蔷薇科植物贴梗海棠的干燥近成熟果实；酸，温；归肝、脾经；具有平肝舒筋、和胃化湿的功效；用于湿痹拘挛、腰膝关节酸重疼痛、吐泻转筋、脚气水肿等症。上述五味中草药，药味不多但功能齐备，5味药用原料按所述配比组合后，治疗痛风具有协同增效功能，经临床研究试验，本发明的中药组合物用于治疗痛风疗程短、见效快，给药4天后，即可见效，且疗效显著，患者服药期间未出现明显不良反应。
具体实施方式
下面结合试验例及具体实施方式对本发明作进一步的详细描述，但不应将此理解为本发明上述主题的范围仅限于以下的实施例，凡基于本发明内容所实现的技术均属于本发明的范围。
本发明的实施例和对比例中所用乙醇均为乙醇的水溶液，乙醇的百分含量，如无特殊说明，均为体积百分含量。
实施例1
本实施例的治疗痛风的中药组合物，是由以下重量配比的药用原料制备而成：佛手12g、猫爪草8g、川芎6g、九香虫6g、木瓜6g。
上述药用原料的提取方法：
(1)按配方比例取各药用原料，向药用原料中加入药用原料体积8～10倍的60～80％乙醇或水；回流提取2～3次；提取时间分别为1～2h；收集合并提取液，并将提取液浓缩至相对密度1.20(80℃)，得到实施例1药用原料的提取物。
(2)向上述提取物中加入提取物重量2倍重量的可溶性淀粉，制粒，干燥，分装成袋，得到颗粒剂。
实施例2
本实施例的治疗痛风的中药组合物，是由以下重量配比的药用原料制备而成：佛手20g、猫爪草8g、川芎7g、九香虫3g、木瓜3g。
按实施例1中药用原料提取方法提取药用原料的活性组分，得到实施例2治疗痛风的中药组合物。
实施例3
本实施例的治疗痛风的中药组合物，是由以下重量配比的药用原料制备而成：佛手14g、猫爪草8g、川芎7g、九香虫5g、木瓜7g。
按实施例1中药用原料提取方法提取药用原料的活性组分，得到实施例3治疗痛风的中药组合物。
对比例
本对比例的治疗痛风的中药组合物，是由以下重量配比的药用原料制备而成：佛手12g、猫爪草8g、川芎6g、木瓜6g。
按实施例1中药用原料提取方法提取药用原料的活性组分，得到对比例治疗痛风的中药组合物。
药效学和毒性试验：
为了证实本发明药物的疗效和安全性，发明人进行了药效学和毒性试验考察。所采用的研究方法及试验结果如下：
1、试验材料
(1)药物及试剂：
根据实施例1制备的实施例1的中药组合物；
根据对比例制备的对比例的中药组合物；
秋水仙碱：为云南植物药业有限公司产品。
(2)动物：昆明种小鼠，由四川抗菌素研究所实验动物中心提供。
2、试验方法与结果
(1)对高尿酸血症小鼠血尿酸水平的影响
取昆明种小鼠50只，雌雄皆用，体重18～22g，随机分为五组，每组10只，第一组为生理盐水组，第二组为本发明药物实验组(8g生药材/kg)，第三组为阳性对照组，第四组为对照组1，第五组为模型组。
对第一组按8g/kg的剂量灌服生理盐水，第二组按8g生药材/kg的剂量灌服本发明实施例1制备的中药组合物，第三组按0.1mg/kg的药剂剂量灌服秋水仙碱，第四组按8g生药材/kg的剂量灌服对比例制备的中药组合物，第五组不作任何处理，每日1次，连续4d。
末次给药1h后，除生理盐水组外，其余各组，即第二组到第五组，动物腹腔注射次黄嘌呤1mg/kg，造成小鼠高血尿酸，生理盐水组按1mg/kg注射生理盐水。注射后0.5h，对各组动物摘眼球取血，将取得的血液在3000r/min的转速条件下离心15min后，取血清测血尿酸值。表1为各实验组和对照组经处理后，血尿酸测量值的统计结果。
表1
注：与模型组比较:**P<0.01；与对照组1比较:▲▲P<0.01。
表1中,本发明药物实验组测得血尿酸值为173±22umol/l：与生理盐水组的血尿酸值136±23umol/l及阳性对照组的血尿酸值155±26umol/l接近；相对模型组测得的血尿酸值754±93umol/l降低了580umol/l左右，且本发明药物实验组的统计结果相对于模型组P<0.01，具有显著性差异；本发明治疗痛风的中药组合物治疗痛风具有很好的疗效。
而表1中,对照组1测得血尿酸值为272±29umol/l，相对本发明药物实验组测得血尿酸值为173±22umol/l高出近100umol/l。且本发明药物实验组的血尿酸测量值较对照组1的血尿酸测量值P＜0.01，具有显著性差异。由此得知，5味药用原料按所述重量配比组合后，具有协同增效功能，能显著提高中药组合物的疗效，缺少任意组分，中药组合物的疗效均显著下降。
综上所述，本发明治疗痛风的中药组合物，治疗痛风的疗程短，见效快，给药4天即可见效，疗效显著。给药4天后注射次黄嘌呤，本发明药物实验组的血尿酸测量值均不会发生显著升高现象；5味药用原料按所述重量配比组合后，具有协同增效功能，能显著提高中药组合物的疗效。缺少任意组分，其疗效均显著下降，如对照组1，注射次黄嘌呤后，测得血尿酸值相对本发明药物实验组的血尿酸测量值升高近100umol/l。
Claims (10)
1.一种含九香虫的治疗痛风的中药组合物，其特征在于：它是由以下重量配比的药用原料制备而成：佛手4～20份、猫爪草3～15份、川芎3～10份、九香虫3～10份、木瓜3～10份。
2.根据权利要求1所述的治疗痛风的中药组合物，其特征在于：佛手所占重量比例为8～15份。
3.根据权利要求2所述的治疗痛风的中药组合物，其特征在于：佛手所占重量比例为12份。
4.根据权利要求1所述的治疗痛风的中药组合物，其特征在于：猫爪草所占重量比例为6～10份。
5.根据权利要求4所述的治疗痛风的中药组合物，其特征在于：猫爪草所占重量比例为8份。
6.根据权利要求1所述的治疗痛风的中药组合物，其特征在于：川芎所占重量比例为4～7份。
7.根据权利要求6所述的治疗痛风的中药组合物，其特征在于：川芎所占重量比例为6份。
8.根据权利要求1所述的治疗痛风的中药组合物，其特征在于：九香虫所占重量比例为4～7份。
9.根据权利要求8所述的治疗痛风的中药组合物，其特征在于：九香虫所占重量比例为6份。
10.根据权利要求1所述的治疗痛风的中药组合物，其特征在于：木瓜所占重量比例为4～7份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410628473.6A CN104337909B (zh) | 2014-11-07 | 2014-11-07 | 一种含九香虫的治疗痛风的中药组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410628473.6A CN104337909B (zh) | 2014-11-07 | 2014-11-07 | 一种含九香虫的治疗痛风的中药组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104337909A CN104337909A (zh) | 2015-02-11 |
| CN104337909B true CN104337909B (zh) | 2016-06-22 |
Family
ID=52494901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410628473.6A Active CN104337909B (zh) | 2014-11-07 | 2014-11-07 | 一种含九香虫的治疗痛风的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104337909B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114272343B (zh) * | 2021-12-24 | 2023-05-02 | 黑龙江儒泰科技发展有限责任公司 | 一种用于治疗女性痛风性关节炎的中药组合物及其制备方法和应用 |
| CN117442660B (zh) * | 2023-10-30 | 2024-08-09 | 成都中医药大学 | 一种具有改善睡眠的精油组合物、复合精油纳米纤维及其纺织品 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101518630A (zh) * | 2008-02-28 | 2009-09-02 | 北京中泰天和科技有限公司 | 一种抗痛风的中药组合物及其制备方法 |
| AU2011100558A4 (en) * | 2011-05-16 | 2011-06-23 | G & W Aust Pty Ltd | Herbal compositions and uses for symptomatic relief of tinnitus, migraine, headaches, vertigo, insomnia and sleeplessness |
| CN102940709A (zh) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | 治疗痛风的药物组合物 |
-
2014
- 2014-11-07 CN CN201410628473.6A patent/CN104337909B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101518630A (zh) * | 2008-02-28 | 2009-09-02 | 北京中泰天和科技有限公司 | 一种抗痛风的中药组合物及其制备方法 |
| AU2011100558A4 (en) * | 2011-05-16 | 2011-06-23 | G & W Aust Pty Ltd | Herbal compositions and uses for symptomatic relief of tinnitus, migraine, headaches, vertigo, insomnia and sleeplessness |
| CN102940709A (zh) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | 治疗痛风的药物组合物 |
Non-Patent Citations (1)
| Title |
|---|
| 夏枯草是肺科良药;刘清珍等;《中医杂志》;19990831;第40卷(第8期);第453页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104337909A (zh) | 2015-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105749179A (zh) | 治疗代谢综合征的中药组合物 | |
| CN102940695A (zh) | 治疗痛风的药物组合物 | |
| CN104173458B (zh) | 一种具有防治高尿酸血症作用的中药组合物及其制备方法 | |
| CN102106965B (zh) | 一种治疗软组织急性损伤的组合物及其应用 | |
| CN103877438B (zh) | 治疗痛风的中药制剂及其生产方法 | |
| CN104337909B (zh) | 一种含九香虫的治疗痛风的中药组合物 | |
| CN104208643A (zh) | 一种治疗半身不遂的中药及其制备方法 | |
| CN104435567A (zh) | 一种含绞股蓝的治疗痛风的中药组合物 | |
| CN102940709B (zh) | 治疗痛风的药物组合物 | |
| CN103610795A (zh) | 一种杜仲降压口服制剂的制备方法 | |
| CN102068674A (zh) | 一种治疗慢性泄泻的中药组合物及其制备方法 | |
| CN102940747B (zh) | 治疗痛风的药物组合物 | |
| CN102940850B (zh) | 治疗痛风的药物组合物 | |
| CN112717097A (zh) | 一种治疗胃癌的中药组合物及其制备方法 | |
| CN104337898B (zh) | 一种含郁李仁的治疗痛风的中药组合物 | |
| CN105477465A (zh) | 一种具有保护肝功能的中药制剂及其制备工艺 | |
| CN104435079A (zh) | 一种治疗痛风的中药组合物 | |
| CN104352672A (zh) | 一种含龟板的治疗糖尿病的中药组合物 | |
| CN103977154A (zh) | 一种用于保肝护肝的药物组合物 | |
| CN104547800A (zh) | 一种中药制剂在制备治疗酒精性脂肪肝药物中的用途 | |
| CN103432502B (zh) | 一种治疗消化性溃疡病的中成药 | |
| CN104337889B (zh) | 一种含蚯蚓的治疗痛风的中药组合物 | |
| CN104436017A (zh) | 一种含木通的治疗痛风的中药组合物 | |
| CN101028392B (zh) | 一种治疗高脂血症的中成药 | |
| CN104338054A (zh) | 一种含斑兰叶的治疗痛风的中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 610041, No. 12, 9, 911, 88 South Garden Road, Chengdu hi tech Zone, Sichuan, China Patentee after: Chengdu medical road Kang Huaxi medical science and Technology Co.,Ltd. Address before: 610000, No. 12, 9, 911, 88 South Garden Road, Chengdu hi tech Zone, Sichuan, China Patentee before: CHENGDU HUAXI TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231007 Address after: 675099 Zhuangdian Pharmaceutical Park, Gaoxin District, Chuxiong City, Chuxiong Yi Autonomous Prefecture, Yunnan Province Patentee after: Yunnan Kangjian Shanmei Pharmaceutical Co.,Ltd. Address before: No. 911, 9th Floor, Building 12, No. 88 Keyuan South Road, High tech Zone, Chengdu, Sichuan, 610041 Patentee before: Chengdu medical road Kang Huaxi medical science and Technology Co.,Ltd. |